Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older - Top-Institutions - MDSpire

Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older

  • By

  • Keiji Matsuda

  • Takeshi Ogata

  • Nobuhiko Kamitani

  • Kenta Watanabe

  • Ryoji Tokiya

  • Takafumi Hayashi

  • Yoshiyuki Miyaji

  • Kazumasa Komura

  • Tsutomu Tamada

  • Kuniaki Katsui

  • January 7, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology
    • Geriatric Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology

  • #3

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Medical Oncology
    • Urologic Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology

  • #5

    Kawasaki Medical School
    Kawasaki Medical School

    Kurashiki, Okayama Prefecture, Japan

    Key Differentiators

    • Radiation Oncology
    • Geriatric Oncology

Original Source(s)

Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older

  • by Keiji Matsuda, Takeshi Ogata, Nobuhiko Kamitani, Kenta Watanabe, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Kazumasa Komura, Tsutomu Tamada, Kuniaki Katsui

  • January 7, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer